BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 11284724)

  • 1. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
    Hayhurst GP; Harlow J; Chowdry J; Gross E; Hilton E; Lennard MS; Tucker GT; Ellis SW
    Biochem J; 2001 Apr; 355(Pt 2):373-9. PubMed ID: 11284724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
    Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
    Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.
    Keizers PH; Lussenburg BM; de Graaf C; Mentink LM; Vermeulen NP; Commandeur JN
    Biochem Pharmacol; 2004 Dec; 68(11):2263-71. PubMed ID: 15498516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.
    Guengerich FP; Miller GP; Hanna IH; Martin MV; Léger S; Black C; Chauret N; Silva JM; Trimble LA; Yergey JA; Nicoll-Griffith DA
    Biochemistry; 2002 Sep; 41(36):11025-34. PubMed ID: 12206675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
    Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
    Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6.
    Paine MJ; McLaughlin LA; Flanagan JU; Kemp CA; Sutcliffe MJ; Roberts GC; Wolf CR
    J Biol Chem; 2003 Feb; 278(6):4021-7. PubMed ID: 12446689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression, purification, and characterization of mouse CYP2d22.
    Yu AM; Haining RL
    Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent.
    Lussenburg BM; Keizers PH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
    Biochem Pharmacol; 2005 Oct; 70(8):1253-61. PubMed ID: 16135359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
    Marcucci KA; Pearce RE; Crespi C; Steimel DT; Leeder JS; Gaedigk A
    Drug Metab Dispos; 2002 May; 30(5):595-601. PubMed ID: 11950793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.
    Flanagan JU; Maréchal JD; Ward R; Kemp CA; McLaughlin LA; Sutcliffe MJ; Roberts GC; Paine MJ; Wolf CR
    Biochem J; 2004 Jun; 380(Pt 2):353-60. PubMed ID: 14992686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding.
    McLaughlin LA; Paine MJ; Kemp CA; Maréchal JD; Flanagan JU; Ward CJ; Sutcliffe MJ; Roberts GC; Wolf CR
    J Biol Chem; 2005 Nov; 280(46):38617-24. PubMed ID: 16162505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition.
    VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
    Drug Metab Dispos; 2012 Jan; 40(1):47-53. PubMed ID: 21976621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
    Granvil CP; Krausz KW; Gelboin HV; Idle JR; Gonzalez FJ
    J Pharmacol Exp Ther; 2002 Jun; 301(3):1025-32. PubMed ID: 12023534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6.
    Desta Z; Wu GM; Morocho AM; Flockhart DA
    Drug Metab Dispos; 2002 Mar; 30(3):336-43. PubMed ID: 11854155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in enantioselectivity in bufuralol 1''-hydroxylation by the substitution of phenylalanine-120 by alanine in cytochrome P450 2D6.
    Masuda K; Tamagake K; Okuda Y; Torigoe F; Tsuzuki D; Isobe T; Hichiya H; Hanioka N; Yamamoto S; Narimatsu S
    Chirality; 2005 Jan; 17(1):37-43. PubMed ID: 15526337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening.
    Mo SL; Liu WF; Li CG; Zhou ZW; Luo HB; Chew H; Liang J; Zhou SF
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1640-704. PubMed ID: 22039821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
    Yu A; Dong H; Lang D; Haining RL
    Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity.
    Venhorst J; Onderwater RC; Meerman JH; Commandeur JN; Vermeulen NP
    Drug Metab Dispos; 2000 Dec; 28(12):1524-32. PubMed ID: 11095593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.
    Ellis SW; Ching MS; Watson PF; Henderson CJ; Simula AP; Lennard MS; Tucker GT; Woods HF
    Biochem Pharmacol; 1992 Aug; 44(4):617-20. PubMed ID: 1510710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of phenylalanine at position 120 and glutamic acid at position 222 in the oxidation of chiral substrates by cytochrome P450 2D6.
    Masuda K; Tamagake K; Katsu T; Torigoe F; Saito K; Hanioka N; Yamano S; Yamamoto S; Narimatsu S
    Chirality; 2006 Feb; 18(3):167-76. PubMed ID: 16432914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.